Pharmaceuticals - Netherlands

  • Netherlands
  • The Netherlands is expected to see a projected revenue of €5.53bn in the Pharmaceuticals market by 2024.
  • The largest market within this industry is Oncology Drugs, which is projected to reach a market volume of €0.93bn in the same year.
  • The revenue is anticipated to display an annual growth rate (CAGR 2024-2029) of 4.34%, resulting in a market volume of €6.84bn by 2029.
  • When compared globally, United States is projected to generate the highest revenue in this market, with an estimated amount of €578.50bn in 2024.
  • The Netherlands is leading the way in pharmaceutical innovation, with a strong focus on research and development.

Key regions: United States, China, Germany, Japan, Europe

 
Mercado
 
Región
 
Comparación de regiones
 
Moneda
 

Analyst Opinion

The Netherlands is known for its innovative and progressive healthcare system, which makes it an attractive market for pharmaceutical companies.

Customer preferences:
The Dutch population places a high value on accessible and affordable healthcare, which includes access to a wide range of pharmaceuticals. Patients in the Netherlands are generally well-informed and actively involved in their own healthcare decisions, leading to a demand for personalized medicine and treatments tailored to specific needs.

Trends in the market:
One trend in the Dutch pharmaceutical market is the increasing use of e-health and digital tools to improve patient outcomes and reduce healthcare costs. This includes the use of telemedicine, remote monitoring, and mobile health apps. Another trend is the growing demand for sustainable and environmentally-friendly pharmaceutical products and packaging.

Local special circumstances:
The Netherlands is home to several leading pharmaceutical companies and research institutions, including Janssen, MSD, and the Netherlands Cancer Institute. The country also has a strong focus on clinical research and innovation, with a supportive regulatory environment for new drug development and clinical trials.

Underlying macroeconomic factors:
The Dutch pharmaceutical market is influenced by several macroeconomic factors, including government healthcare policies and regulations, healthcare spending, and the aging population. The Dutch government is committed to providing universal healthcare coverage and has implemented policies to control healthcare costs, which may impact pharmaceutical pricing and reimbursement. The aging population in the Netherlands is also driving demand for pharmaceuticals, particularly in the areas of chronic disease management and palliative care.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Visión general

  • Revenue
  • Analyst Opinion
  • Next generation therapy
  • Global Comparison
  • Methodology
  • Key Market Indicators
Espere, por favor